Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2011, XXXI/181: 015-019 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2011, XXXI/181: 015-019

Title: Application activated eptacog alfa in cardiac surgery

Authors: Zagórski M., Goch A.

More details

03/181

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Application activated eptacog alfa in cardiac surgery


Zagórski M., Goch A.

10th Military Hospital in Bydgoszcz, Poland, Department of Cardiology and Cardiac Surgery, Clinical Department of Cardiac Surgery

Severe bleeding in cardiac surgery is often difficult to treatment. Antybleeding drugs often are out of order.
The aim of the study
was to assess the efficacy of activated eptacog alfa treatment of patients with massive postoperative bleeding, which can not be controlled with conventional therapy.
Material and methods
. Activated eptacog alfa was used in 18 patients after cardiac surgery. The patients had normal results of coagulation screening prior to surgery. We evaluated the average blood loss prior to and after administration of activated eptacog alfa. The average dose was 30.95 mcg/kg following administration of drugs antybleeding, transfusion KKCz, FFP, cryoprecipitate, PLT was decided to include the treatment of activated eptacog alfa.
Results
. At a dose of 30.95 mcg/kg, bleeding stopped in 12 patients. 6 patients required reoperation because of persistent bleeding.
Conclusions
. Administration of activated eptacog alfa clearly limits the amount of transfused blood products. Activated eptacog alfa improves outcomes in patients with intractable postoperative bleeding cardiac surgery. Stops bleeding in patients who received preoperative clopidogrel. 1 patient required reoperation after administration of activated eptacog alfa.

Key words: activated eptacog alfa, bleeding, cardiac surgery, haemorrhagic shock

Pol. Merk. Lek., 2011, XXXI, 181, 15